DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Anakinra to Prevent Adverse Post-infarction Remodeling (2)

Information source: Virginia Commonwealth University
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Acute Myocardial Infarction; Heart Failure

Intervention: Anakinra (Drug); Placebo (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Virginia Commonwealth University

Official(s) and/or principal investigator(s):
Antonio Abbate, M.D., Ph.D., Principal Investigator, Affiliation: Virginia Commonwealth University

Summary

Acute myocardial infarction (AMI) remains a major cause of morbidity and mortality. Many patients die early during the course, and those who survive are at risk for dying late from adverse cardiac remodeling and heart failure.

The initial ischemic damage to the myocardium initiates an intense inflammatory response in promoting further cardiac dysfunction and heart failure. The investigators propose that an antiinflammatory strategy based on blockade of Interleukin-1 will quench the inflammatory response and lead to a more favorable cardiac remodeling process.

Clinical Details

Official title: Anakinra to Prevent Adverse Post-infarction Remodeling (2)

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Difference between the anakinra arm and the placebo arm in change in left ventricular end-systolic volume indices from baseline to follow up exam at cardiac magnetic resonance imaging

Secondary outcome:

Difference between the anakinra arm and the placebo arm in change in left ventricular end-diastolic volume indices and ejection fraction values from baseline to follow up exam at cardiac magnetic resonance imaging

Difference between the 2 arms in percentage of patients with: a) reverse remodeling [reduction in LVESVi or LVEDVi >5% or >10%]; b) adverse remodeling [increase >5% or >10%]; c) left ventricular ejection fraction change >5% or >10%

Difference between the 2 arms in the peak VO2 or VE/VCo2 slope at 14 days, 10-14 weeks or the interval change in such measures

Difference between the anakinra arm and the placebo arm in percentage of patients with a new diagnosis or admission to the hospital for heart failure

Difference between the 2 arms in the number of adverse events including (a) all events; (b) events requiring unblinding; (c) events requiring termination; (d) death

Difference between the 2 arm in the interval change in right ventricular dimensions and function

Detailed description: Acute myocardial infarction (AMI) remains a major cause of morbidity and mortality. Many patients die early during the course, and those who survive are at risk for dying late from adverse cardiac remodeling and heart failure.

The initial ischemic damage to the myocardium initiates an intense inflammatory response in promoting further cardiac dysfunction and heart failure. Interleukin-1 (IL-1) is the prototypical inflammatory cytokine involved in the tissue response to injury. In the experimental model of large anterior wall AMI in the mouse, IL-1 blockade using anakinra, a recombinant human IL-1 receptor antagonist ameliorates cardiac remodeling and improves survival following AMI. Although the mouse AMI model is helpful in understanding the events leading to adverse post-infarction cardiac remodeling and heart failure, the exact role of IL-1 in patients with AMI has not been completely characterized. The investigators propose to address this question by studying patients presenting with ST-segment elevation AMI (STEMI). Such patients are at high risk for in-hospital and long-term mortality and display several markers of inflammation. The investigators hypothesize that IL-1 blockade in patients STEMI with will limit the acute inflammatory response and prevent adverse cardiac remodeling, heart failure, and related morbidity.

The investigators hypothesize that treatment with anakinra will lead to more favorable cardiac remodeling. Left ventricular end-systolic volume index (LVESVi) is the preferred clinical marker of adverse cardiac remodeling and a strong predictor of heart failure-related mortality in patients with STEMI, and will be used as primary endpoint of the study. The investigators propose that anakinra will reduce the change in LVESVi from baseline to 10-14 weeks after STEMI, and will prevent, at least in part, other changes in cardiac function and exercise tolerance associated with adverse cardiac remodeling and heart failure.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients with STEMI will be asked to enroll according to the following inclusion

criteria:

- age > 18 years,

- acute (<12 h) onset of chest pain associated with ST segment elevation (>2 mm)

in 2 or more anatomically contiguous leads at ECG,

- and successful primary percutaneous coronary intervention.

Exclusion criteria:

- inability to give informed consent,

- late presentation (>12 h),

- unsuccessful revascularization procedure,

- hemodynamic instability including hypotension,

- prior Q-wave AMI,

- end-stage congestive heart failure (AHA/ACC class C-D, New York Heart Association

IV), severe left ventricular dysfunction (EF<20%),

- severe valvular heart disease,

- pregnancy, dye allergy or contraindications to cardiac angiography and/or magnetic

resonance imaging, coagulopathy (INR>1. 5 or platelet count<50000/mm3),

- recent (<14 days) use of anti-inflammatory drugs (not including NSAIDs),

- chronic inflammatory disease (including but not limited to rheumatoid arthritis,

systemic lupus erythematosus), and malignancy or any comorbidity limiting survival or conditions predicting inability to complete the study.

Locations and Contacts

Virginia Commonwealth University, Richmond, Virginia 23298, United States; Recruiting
Antonio Abbate, MD, PhD, Phone: 804-828-0513, Email: aabbate@mcvh-vcu.edu
Lenore Roach, NP, Phone: 804-8281601, Email: lmroach@vcu.edu
Antonio Abbate, MD, PhD, Principal Investigator
Additional Information

VCU Pauley Heart Center

Related publications:

Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R, Roach LM, Arena RA, Roberts CS, Varma A, Gelwix CC, Salloum FN, Hastillo A, Dinarello CA, Vetrovec GW; VCU-ART Investigators. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol. 2010 May 15;105(10):1371-1377.e1. Epub 2010 Apr 2.

Starting date: July 2010
Last updated: March 13, 2012

Page last updated: February 07, 2013

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012